Major Adverse Cardiac Events
15
5
5
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
13%
2 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (15)
Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL
Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data
Impact of Assessment and Management of Comorbidities in Internal Medicine on Cardiovascular Risk
TTE Improves Clinical Management of Stable Chest Pain
Preoperative Cardiology Consultation and the Incidence of Major Adverse Cardiac Events（MACE）
Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation
Predictive Value of NT-proBNP on MACEs After Acute Coronary Syndrome
Construction of a Prediction Model for MACCE in Elderly Patients After Elective Non-cardiac Surgery
Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT： Cohort Study
Effect of Patient Management Based on Continuous Continuous Glucose Monitoring on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes and Moderate to Severe Coronary Artery Stenosis
Novel Cardiovascular Biomarkers in Patients With Kidney Disease
Echo-guided Hemodynamic Management Strategy in Elderly Patients Undergoing Noncardiac Surgery
Adverse Events in Acute Limb Ischemic Patient Undergoing Revascularization
Colchicine Prevents Myocardial Injury After Non-Cardiac Surgery Pilot Study
Impact of OSA on Outcomes in Acute Coronary Syndrome